The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results* (Q35539691)
Jump to navigation
Jump to search
scientific article published on September 1, 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results* |
scientific article published on September 1, 2003 |
Statements
1 reference
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results (English)
1 reference
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results* (English)
Jean-François Dhainaut
1 reference
Pierre-François Laterre
1 reference
Howard Levy
1 reference
Darell Heiselman
1 reference
Peter Morris
1 reference
Roland Schein
1 reference
Jean-Pierre Sollet
1 reference
Dennis Maki
1 reference
Steven P. LaRosa
Gary E. Garber
Gary T. Kinasewitz
R. Bruce Light
Becky M. Bates
Barbara G. Utterback
1 September 2003
1 reference
1 reference
31
1 reference
9
1 reference
2291-2301
1 reference
Identifiers
1 reference
1 reference